Strides Arcolab receives US FDA approval for HIV drug

Strides Arcolab on May 15, 2015 announced that it has received the approval from US Food & Drug Administration (US FDA) for lamivudine and zidovudine tablets USP, 150 mg/ 300 mg – a generic version of ViiV Healthcare’s Combivir.
 
According to IMS data, the market for lamivudine and zidovudine tablets is approximately $ 120 million in the US. Lamivudine and zidovudine tablet belongs to a group of anti-viral medicines, also known as anti-retrovirals, and is used with other anti-retroviral medicines to treat HIV infection in adults and children.
 
The product, which will be launched in the markets immediately, will be manufactured at Strides Arcolab’s oral dosage facility in Bangalore and marketed by Strides in the US market.